Aug 07, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
Aug 07, 2025 • Benzinga
NEUTRAL
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Aug 07, 2025 • Motley Fool
BULLISH
Adma Biologics ( ADMA ) Q2 Revenue Up 14%
Adma Biologics ( NASDAQ:ADMA ) , a plasma-derived biologics manufacturer focused on immunotherapies, released its earnings for Q2 2025 on August 6, 2025. The quarter showed continued revenue growth, with GAAP total revenue of $122.0 million, with total revenue ( GAAP ) reaching $122.0 million, ...
Aug 06, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Adma Biologics ( ADMA ) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of +7.14% and +0.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 01, 2025 • Benzinga
SOMEWHAT-BULLISH
Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has fallen 10.9% since its last report. The company recently reported that it has 14.47 million shares sold short, which is 7.44% of all regular shares that are available for trading.
Jul 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Adma Biologics ( ADMA ) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.